Zoetis (ZTS) Advances But Underperforms Market: Key Facts

Company Performance - Zoetis (ZTS) closed at $152.30, reflecting a +0.92% change from the previous day, which is lower than the S&P 500's gain of 2.03% [1] - Over the past month, Zoetis shares have decreased by 7.31%, which is less than the Medical sector's decline of 8.57% and the S&P 500's drop of 5.07% [1] Upcoming Earnings - The earnings report for Zoetis is scheduled for May 6, 2025, with an expected EPS of$ 1.40, indicating a growth of 1.45% compared to the same quarter last year [2] - The Zacks Consensus Estimate for revenue is projected at $2.19 billion, reflecting a slight increase of 0.02% from the previous year [2] Full Year Projections - For the full year, the Zacks Consensus Estimates predict earnings of$ 6.07 per share and revenue of $9.31 billion, representing increases of +2.53% and +0.55% respectively from the prior year [3] - Recent changes in analyst estimates indicate a positive outlook for Zoetis, suggesting optimism regarding the company's business and profitability [3] Valuation Metrics - Zoetis has a Forward P/E ratio of 24.85, which is a premium compared to its industry's Forward P/E of 15.31 [5] - The company has a PEG ratio of 2.64, while the Medical - Drugs industry has an average PEG ratio of 1.16 [6] Industry Ranking - The Medical - Drugs industry, which includes Zoetis, ranks in the top 24% of all industries, with a current Zacks Industry Rank of 59 [6] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, indicating that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [7]